{"id":"placebo-of-baloxavir-marboxil-tablets","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL4297503","moleculeType":"Small molecule","molecularWeight":"571.56"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"As a placebo of Baloxavir Marboxil, this formulation contains no active drug substance and serves as a control arm in clinical trials. Baloxavir Marboxil itself is a cap-dependent endonuclease inhibitor that blocks viral polymerase function, but the placebo formulation is inert and produces no therapeutic effect.","oneSentence":"This is a placebo control formulation with no active pharmacological mechanism.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:28:01.830Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Control arm in Phase 3 clinical trials of Baloxavir Marboxil for influenza treatment or prophylaxis"}]},"trialDetails":[{"nctId":"NCT06507813","phase":"PHASE3","title":"Safety and Efficacy of ADC189 in Children 2-11 Years Old With Influenza","status":"COMPLETED","sponsor":"Jiaxing AnDiCon Biotech Co.,Ltd","startDate":"2024-08-19","conditions":"Influenza Type A, Influenza Type B","enrollment":190},{"nctId":"NCT03969212","phase":"PHASE3","title":"Study to Assess the Efficacy of Baloxavir Marboxil Versus Placebo to Reduce Onward Transmission of Influenza A or B in Households","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2019-10-10","conditions":"Influenza","enrollment":4138},{"nctId":"NCT06205641","phase":"NA","title":"A Prospective, Multicenter, Randomized Controlled Clinical Study on the Efficacy and Safety of Xuanfei Baidu Granule in the Treatment of Influenza A","status":"UNKNOWN","sponsor":"Capital Medical University","startDate":"2024-01","conditions":"Influenza A","enrollment":584},{"nctId":"NCT02949011","phase":"PHASE3","title":"Study of S-033188 (Baloxavir Marboxil) Compared With Placebo or Oseltamivir in Patients With Influenza at High Risk of Influenza Complications","status":"COMPLETED","sponsor":"Shionogi","startDate":"2017-01-11","conditions":"Influenza","enrollment":2184},{"nctId":"NCT02954354","phase":"PHASE3","title":"A Study of S-033188 (Baloxavir Marboxil) Compared With Placebo or Oseltamivir in Otherwise Healthy Patients With Influenza","status":"COMPLETED","sponsor":"Shionogi","startDate":"2016-12-08","conditions":"Influenza","enrollment":1436}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo of Baloxavir Marboxil tablets","genericName":"Placebo of Baloxavir Marboxil tablets","companyName":"Jiaxing AnDiCon Biotech Co.,Ltd","companyId":"jiaxing-andicon-biotech-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This is a placebo control formulation with no active pharmacological mechanism. Used for Control arm in Phase 3 clinical trials of Baloxavir Marboxil for influenza treatment or prophylaxis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}